Investors

2016 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/15/16Medgenics, Inc. Announces Name Change to Aevi Genomic Medicine, Inc.
PHILADELPHIA, Dec. 15, 2016 /PRNewswire/ -- Medgenics, Inc. (NASDAQ: MDGN) today announced that the company has changed its name to Aevi Genomic Medicine, Inc.  Aevi Genomic Medicine (pronounced "AHH-vee") is a name inspired by the Old Norse language which means "life story" and reflects the Company's mission of improving the lives of children and adults with pediatric onset life-altering diseases.    "The past year has been a period of transformational chan... 
Printer Friendly Version
11/22/16Medgenics to Present at the 28th Annual Piper Jaffray Healthcare Conference
PHILADELPHIA, PA -- (Marketwired) -- 11/22/16 -- Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, November 30, 2016 at 11:00 AM EST at the Lotte New York Palace Hotel, New York. About Medgenics, Inc. Medgenics is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its effo... 
Printer Friendly Version
11/09/16Medgenics to Present at the Jefferies London Healthcare Conference
PHILADELPHIA, PA -- (Marketwired) -- 11/09/16 -- Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies London Healthcare Conference in London, UK on Thursday, November 17, 2016 at 10:40 a.m. GMT at the Waldorf Hilton, London, UK. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.medgenics.com or you may use the link: http://wsw.co... 
Printer Friendly Version
11/03/16Medgenics Reports Third Quarter 2016 Financial Results
PHILADELPHIA, PA -- (Marketwired) -- 11/03/16 -- Medgenics, Inc. (NASDAQ: MDGN) Presented Data Confirming Prevalence of Genetic Mutations in Pediatric ADHD at the 63rd Annual American Academy of Child and Adolescent Psychiatry (AACAP) Meeting Began Trading on the NASDAQ Global Markets Medgenics, Inc. (NASDAQ: MDGN) (the Company) today announced third quarter 2016 financial results and provided a business update. "We are pleased with the Company's ac... 
Printer Friendly Version
10/29/16Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder
PHILADELPHIA, Oct. 29, 2016 /PRNewswire/ -- Medgenics, Inc. (NASDAQ: MDGN) – New data presented at AACAP's 63rd Annual Meeting (Oct. 24-29, 2016 in New York, NY) confirmed the presence of specific genetic mutations in many children with Attention Deficit Hyperactivity Disorder (ADHD).  The study team, led by Dr. Josephine Elia, M.D., Neuroscience Center, Department of Child and Adolescent Psychiatry, Nemours/Alfred I. DuPont Hospital for Children, studied a US population of children suffering fr... 
Printer Friendly Version
10/26/16Medgenics to Host Conference Call to Announce Third Quarter 2016 Financial Results
PHILADELPHIA, PA -- (Marketwired) -- 10/26/16 -- Medgenics, Inc. (NASDAQ: MDGN) will host a conference call and live audio webcast on Thursday, November 3, 2016 at 8:30 a.m. EST to report financial results for the third quarter ended September 30, 2016 and discuss recent business updates. In order to participate in the conference call, please dial (888) 576-4380 (domestic) or (719) 325-2437 (international). The conference passcode is 1910091. The live webcast can be accessed under "Events" i... 
Printer Friendly Version
10/10/16Medgenics, Inc. to Begin Trading on NASDAQ Global Market
PHILADELPHIA, PA -- (Marketwired) -- 10/10/16 -- Medgenics, Inc. (NYSE MKT: MDGN) (the "Company") announced today that it has been approved for listing on the NASDAQ Global Market, continuing to trade under the symbol "MDGN." Trading on the NASDAQ Global Market is expected to commence on October 21, 2016. The Company's common stock will continue to trade on the NYSE Amex until the market close on October 20, 2016. Mike Cola, Chief Executive Officer Medgenics, commented, "We are pleased to ann... 
Printer Friendly Version
09/06/16Medgenics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
PHILADELPHIA, PA -- (Marketwired) -- 09/06/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference in New York, NY on Monday, September 12, 2016 at 9:10 a.m. EDT at the Lotte New York Palace Hotel. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.medgenics.com or you may us... 
Printer Friendly Version
08/04/16Medgenics Reports Second Quarter 2016 Financial Results
PHILADELPHIA, PA -- (Marketwired) -- 08/04/16 -- Medgenics, Inc. (NYSE MKT: MDGN) Initiated Phase 2/3 study of lead program in mGluR+ ADHD Entered into collaboration for second pediatric product in Inflammatory Bowel Disease Strengthened balance sheet with successful financing Medgenics, Inc. (NYSE MKT: MDGN) (the Company) today announced second quarter 2016 financial results and provided a business update. "We are very pleased with ... 
Printer Friendly Version
07/27/16Medgenics to Host Conference Call to Announce Second Quarter 2016 Financial Results
PHILADELPHIA, PA -- (Marketwired) -- 07/27/16 -- Medgenics, Inc. (NYSE MKT: MDGN) will host a conference call and live audio webcast on Thursday, August 4, 2016 at 8:30 a.m. EDT to report financial results for the second quarter ended June 30, 2016 and discuss recent business updates. In order to participate in the conference call, please dial (877) 718-5098 (domestic) or (719) 325-4917 (international). The conference passcode is 4998119. The live webcast can be accessed under "Events" in th... 
Printer Friendly Version
06/21/16Medgenics Announces Pricing of Public Offering of Common Stock
PHILADELPHIA, PA -- (Marketwired) -- 06/21/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced the pricing of 3,640,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $5.50 per share. In connection with the offering, Medgenics has also granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered to the public. Gross proceeds to Medgenics from the sale of shares are expected t... 
Printer Friendly Version
06/20/16Medgenics Announces Public Offering of Common Stock
PHILADELPHIA, PA -- (Marketwired) -- 06/20/16 -- Medgenics, Inc. (NYSE: MDGN), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. All of the shares to be sold in the proposed offering are being sold by Medgenics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed,... 
Printer Friendly Version
06/17/16Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD
PHILADELPHIA, PA -- (Marketwired) -- 06/17/16 -- Medgenics, Inc. (NYSE: MDGN) today announced the enrollment of the first patient into the SAGA (Study of Adolescent Glutamate Receptor Network Copy Number Variant ADHD) trial -- a Phase 2/3 clinical trial to evaluate adolescent patients with mGluR mutation positive (mGluR+) attention deficit disorder (ADHD). "Enrollment of our first patient is a critical milestone for Medgenics, as it brings us one step closer to offering an innovative precisio... 
Printer Friendly Version
06/15/16Medgenics to Present at the JMP Life Sciences Conference
PHILADELPHIA, PA -- (Marketwired) -- 06/15/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the JMP Life Sciences Conference at 12:30 PM Eastern Time on Tuesday, June 21, 2016 in New York, NY. About Medgenics, Inc. Medgenics is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ... 
Printer Friendly Version
06/06/16Medgenics Obtains Rights to First-in-Class Biologic for Severe Pediatric Onset IBD
PHILADELPHIA, PA -- (Marketwired) -- 06/06/16 -- (NYSE MKT: MDGN) Collaboration with Kyowa Hakko Kirin to develop anti-LIGHT monoclonal antibody Second program from research collaboration with The Children's Hospital of Philadelphia (CHOP) Center for Applied Genomics (CAG) Data from signal finding study in Severe Pediatric Onset Inflammatory Bowel Disease patients expected in first half 2017 Medgenics, Inc. (NYSE MKT: MDGN) today announce... 
Printer Friendly Version
06/01/16Medgenics to Present at the Jefferies 2016 Global Healthcare Conference
PHILADELPHIA, PA -- (Marketwired) -- 06/01/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies 2016 Global Healthcare Conference in New York, NY on Tuesday, June 7, 2016 at 3:30 p.m. EDT at the Grand Hyatt New York. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.medgenics.com or you may use the link: http:/... 
Printer Friendly Version
05/20/16Medgenics to Present at the UBS Global Healthcare Conference
PHILADELPHIA, PA -- (Marketwired) -- 05/20/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the annual UBS Global Healthcare Conference in New York, NY on Wednesday May 25, 2016 at 8:00 a.m. EDT at the Grand Hyatt New York. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.medgenics.com or you may use the link: https://cc.talkpoint... 
Printer Friendly Version
05/10/16Medgenics Reports First Quarter 2016 Financial Results and NFC-1 Program Update
PHILADELPHIA, PA -- (Marketwired) -- 05/10/16 -- Medgenics, Inc. (NYSE MKT: MDGN) Rapid enrollment in phenotype/genotype study of mGluR positive ADHD patients Data support the prevalence of mGluR mutation in broad ADHD population Enrollment to begin in Phase 2/3 clinical trial in mGluR+ ADHD patients Enrollment to begin in Phase 1/2 clinical trial in 22q Deletion Syndrome patients Medgenics, Inc. (NYSE MKT: MDGN) (the Com... 
Printer Friendly Version
05/03/16Medgenics Hires Michael Diem as Senior Vice President of Business and Corporate Development
PHILADELPHIA, PA -- (Marketwired) -- 05/03/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced the appointment of Michael Diem, MD as Senior Vice President of Corporate and Business Development. Dr. Diem will be a key member of the Medgenics leadership team, heading all business and corporate development activities. Mike was recently with AstraZeneca as the Head of Corporate Strategy and Corporate Development, where he was responsible globally for corporate strategy, corporate development an... 
Printer Friendly Version
05/02/16Medgenics to Host Conference Call to Announce First Quarter 2016 Financial Results
PHILADELPHIA, PA -- (Marketwired) -- 05/02/16 -- Medgenics, Inc. (NYSE MKT: MDGN) will host a conference call and live audio webcast on Tuesday, May 10, 2016 at 8:30 a.m. EDT to discuss the financial results for the first quarter ended March 31, 2016. In order to participate in the conference call, please dial (888) 576-4387 (domestic) or (719) 325-2402 (international). The conference passcode is 2282249. The live webcast can be accessed under "Events" in the Investors section of the Company... 
Printer Friendly Version
04/20/16Medgenics Hires Eric Phillips, MPH, ScD as Vice President of Regulatory Affairs
PHILADELPHIA, PA -- (Marketwired) -- 04/20/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced the appointment of Eric Phillips, MPH, ScD as Vice President of Regulatory Affairs. In this role, Dr. Phillips will be a key member of the Medgenics leadership team setting the strategy and tactics for all regulatory activities. Dr. Phillips has held positions of increasing responsibility in Regulatory Affairs, most recently at Bristol-Myers Squibb, where he led the successful submission for the a... 
Printer Friendly Version
03/30/16Medgenics to Present at the 15th Annual Needham Healthcare Conference
PHILADELPHIA, PA -- (Marketwired) -- 03/30/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced that Brian Piper, Chief Financial Officer, will present at the 15th Annual Needham Healthcare Conference in New York, NY. The event will take place on Wednesday April 13, 2016 at 10:00 a.m. EDT at the Westin Grand Central Hotel. A live webcast of the presentation can be accessed under the "Presentations" in the Investors section of the Company's website at www.medgenics.com or you may use the li... 
Printer Friendly Version
03/08/16Medgenics Hires Rick Couch, Ph.D. to Vice President of Chemistry, Manufacturing and Controls
PHILADELPHIA, PA -- (Marketwired) -- 03/08/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced the appointment of Rick Couch, Ph.D., as Vice President of Chemistry, Manufacturing and Controls (CMC). In this role, Dr. Couch will be a key member in setting the strategy and tactics of technical product development as well as leading and managing all CMC activities. Dr. Couch has held positions of increasing responsibility in the Pharmaceutical Sciences, most recently at Shire Pharmaceuticals, ... 
Printer Friendly Version
02/17/16CORRECTION - Medgenics Reports Fourth Quarter and Full Year 2015 Results and Advancement of NFC-1 Development Programs
PHILADELPHIA, PA -- (Marketwired) -- 02/17/16 -- In the news release, "Medgenics Reports Fourth Quarter and Full Year 2015 Results and Advancement of NFC-1 Development Programs" issued earlier today by Medgenics Inc (NYSE MKT: MDGN), we are advised by the company that the weighted average number of common stock used in computing basic loss per share should be 26,783,623, not 25,015,130 as originally reported. There were also a few other related changes. Complete corrected text follows. ... 
Printer Friendly Version
02/08/16Medgenics to Host Conference Call to Announce Fourth Quarter and Year End 2015 Financial Results
PHILADELPHIA, PA -- (Marketwired) -- 02/08/16 -- Medgenics, Inc. (NYSE MKT: MDGN) will host a conference call and live audio webcast on Wednesday, February 17, 2016 at 8:30 a.m. ET to discuss fourth quarter and 2015 year end results. In order to participate in the conference call, please dial (888) 337-8169 (domestic) or (719) 325-2464 (international). The conference passcode is 3724050. The live webcast can be accessed under "Events" in the Investors section of the Company's website at www.... 
Printer Friendly Version
02/03/16Medgenics Promotes Brian Piper to Chief Financial Officer
PHILADELPHIA, PA -- (Marketwired) -- 02/03/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced that Brian Piper will become the Company's new Chief Financial Officer effective February 9, 2016. Mr. Piper joined Medgenics in April 2014 as Vice President of Finance and Investor Relations. During that time period, Mr. Piper was highly involved with the Company's efforts to complete two successful equity offerings, raising approximately $70 million. The Company also announced today that Dr. Joh... 
Printer Friendly Version
01/26/16Medgenics to Participate in the 2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day
PHILADELPHIA, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), today announced that members of its management team will participate in the 2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day on Tuesday, February 2, 2016 in New York, NY. About Medgenics, Inc. Medgenics is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sp... 
Printer Friendly Version
01/06/16Medgenics Licenses Novel GeneRide Gene Therapy Technology From Stanford University
PHILADELPHIA, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN), today announced the signing of a license with Stanford University providing exclusive rights to certain breakthrough gene therapy technologies developed in the labs of Professor Mark A. Kay, M.D., Ph.D., Dennis Farrey Family Professor in Pediatrics, Professor of Genetics, at Stanford University School of Medicine. Under the license, Medgenics gains the exclusive right for the autologous ex vivo use of Stanford’s GeneR... 
Printer Friendly Version